Today's Forecast: PM Light Rain, High 37°
Tomorrow: AM Rain/Snow Showers, High 33°
- Two-time Cancer Survivor Recognized
- Name That Yellowjacket
- New Horizons Orchestras to Perform at Nazareth College
- Jefferson Honored for Service to the Community
- Event Highlight: Chamber Orchestra
in the News: Craig Jordan on Cancer Stem Cell Drug Trial; Frederick Marshall Recommends FDA Approval for Drug
- In Higher
Ed: Psychologists Urge Curbs on Corporate Influence
Cancer Survivor Recognized by Wilmot Radiation Oncologists
Georgiana Giuliano Zicari has faced cancer twice and the experiences have made her a vigilant advocate for more research to find cures. Her dedication to supporting people with cancer and the doctors and scientists working for cures is a source of inspiration for many at the Wilmot Cancer Center. Read
Name That Yellowjacket
There's still time to submit your suggestion for the new mascot's name. Submissions can be made through Dec. 14 using the online form or via suggestion boxes located at the Eastman School and on the River Campus. A committee of students, faculty, and staff will review the suggestions and select the top five. Voting for the final selection will begin in January. Read
New Horizons Orchestras to Perform at Nazareth College
The New Horizons Symphony Orchestra and String Orchestra will present their first concert of the season under the direction of Nancy Strelau at 10:30 a.m. Dec. 19 in the Linehan Chapel at Nazareth College. Read
Jefferson Honored for Service to the Community
Frederick Jefferson, professor emeritus who oversees the Warner School's Leadership and Organizational Development program, has been recognized locally for his volunteerism and leadership in the community. Read
Tuesday, Dec. 11
Chamber Orchestra: Strong Auditorium. 8 p.m.
For more events: www.rochester.edu/calendar
in the News
LA Times (Dec. 10)
"War on Cancer Moves to a New Front "
Craig Jordan, professor of medicine and director of Translational Research for Hematologic Malignancies, discusses his trial of a cancer drug based on a chemical from the feverfew plant. "As yet, very little has happened that has clinical relevance, but we are right on the cusp of making the transition." Read
Reuters (Dec. 10)
"FDA Advisory Committee Votes Unanimously to Recommend Approval of Tetrabenazine "
Frederick Marshall, associate professor of neurology and chief of the Geriatric Neurology Unit, urges an advisory committee to the U.S. Food and Drug Administration to approve Tetrabenazine for the treatment of Huntington’s disease. "Patients and physicians do not have any approved treatments to alleviate this disorder or any aspect of Huntington disease." Read
The Chronicle of Higher Education (Dec. 10)
"American Psychological Association Panel Urges Curbs on Corporate Influence on the Discipline "
"The profession of psychology should become far more vigilant in repelling the influence of corporations, particularly pharmaceutical companies, suggests a report from the American Psychological Association's Presidential Task Force on External Funding." Read
We want to hear
and feedback to email@example.com